Anesthesiology Research Analysis
February’s anesthesiology research converged on targetable neuro-immune mechanisms and pragmatic bedside decision tools. Cross-species mechanistic work identified enteric glial connexin‑43 as a druggable driver of postoperative ileus, while a randomized trial showed cholinergic immunomodulation with low‑dose neostigmine reduced inflammation and 28‑day mortality in septic shock. Precision pain biology advanced with Cell’s mapping of OSMR/SST‑marked sleeping nociceptors, opening biomarker‑guided a
Summary
February’s anesthesiology research converged on targetable neuro-immune mechanisms and pragmatic bedside decision tools. Cross-species mechanistic work identified enteric glial connexin‑43 as a druggable driver of postoperative ileus, while a randomized trial showed cholinergic immunomodulation with low‑dose neostigmine reduced inflammation and 28‑day mortality in septic shock. Precision pain biology advanced with Cell’s mapping of OSMR/SST‑marked sleeping nociceptors, opening biomarker‑guided analgesic development. Two practice‑refining clinical studies reported no routine advantage of McGrath videolaryngoscopy over direct laryngoscopy for elective rapid‑sequence intubation and validated the AURIS score to stratify candidemia risk among Candida auris–colonized ICU patients. Collectively, these findings prioritize biomarker‑informed organ‑protection trials, selective airway device use, and risk‑adapted antifungal stewardship alongside scalable digital/neuromodulatory tools.
Selected Articles
1. Glial Connexin-43 is a pathogenic mechanism promoting gut inflammation after postsurgical intestinal manipulation with potential relevance to humans.
This translational study identifies enteric glial connexin‑43 as a highly expressed, surgery‑upregulated hemichannel driving enteric gliosis, immune activation, inflammation, and neuropathy underlying postoperative ileus. Glial‑specific deletion and the peptide inhibitor 43Gap26 attenuated pro‑inflammatory signaling and POI features in mice, with supportive expression patterns in human surgical tissues and human enteric glia.
Impact: Defines a tractable, cell‑specific signaling node that links surgical trauma to POI across species, creating a clear pathway to peptide or small‑molecule hemichannel modulators for perioperative organ‑protection trials.
Clinical Implications: Supports development of selective Cx43 hemichannel modulators and perioperative trials incorporating enteric gliosis/inflammation biomarkers to prevent POI in high‑risk abdominal surgery.
Key Findings
- Cx43 is the predominant connexin in enteric glia (mouse and human) and is upregulated after surgical manipulation.
- Glial‑specific Cx43 deletion mitigated glial reactivity, pro‑inflammatory signaling, immune activation, and prevented enteric neuropathy in a mouse POI model.
- IL‑1β opens Cx43 hemichannels in human enteric glia to increase IL‑6/CCL2 release; 43Gap26 blocks these responses; human surgical samples showed concordant Cx43 upregulation.
2. Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial.
A double‑blind randomized trial showed that continuous low‑dose neostigmine (0.2 mg/hr for 5 days) significantly reduced TNF‑α at day 5, improved SOFA trajectories, and decreased 28‑day mortality (26% vs 54%) in septic shock, supporting augmentation of the cholinergic anti‑inflammatory pathway as adjunctive therapy.
Impact: Delivers randomized evidence of a mortality benefit using an inexpensive, widely available drug via a defined immunomodulatory mechanism—practice‑changing potential if replicated.
Clinical Implications: Pending multicenter replication, protocols may consider neostigmine infusion as an adjunct in septic shock while closely monitoring hemodynamics and anticholinesterase effects.
Key Findings
- Day‑5 TNF‑α was significantly lower with neostigmine (40±36 vs 67±43 pg/mL; p=0.002).
- SOFA trajectories improved in the neostigmine arm.
- 28‑day mortality decreased (26% vs 54%; p=0.02).
3. Molecular architecture of human dermal sleeping nociceptors.
Patch‑seq and cross‑species transcriptomics identified OSMR and SST as markers of mechano‑insensitive C‑fiber nociceptors, with oncostatin M selectively modulating these fibers in human volunteers, defining a targetable human nociceptor subtype for neuropathic‑pain interventions.
Impact: Establishes a human, targetable nociceptor subtype with translational human modulation, enabling biomarker‑driven analgesic development and patient stratification.
Clinical Implications: Supports development of agents or neuromodulation targeting OSMR/SST‑expressing nociceptors; may inform perioperative neuropathic pain prevention and chronic pain management.
Key Findings
- OSMR and SST are marker genes for mechano‑insensitive C‑fiber nociceptors (CMis).
- Oncostatin M selectively modulates CMis in human volunteers.
- Cross‑species transcriptomics aligned human and animal CMis phenotypes.
4. McGrath videolaryngoscopy versus direct laryngoscopy for rapid sequence intubation: A multicenter randomized clinical trial.
In a multicenter randomized trial (n=400) of elective rapid‑sequence intubation, McGrath videolaryngoscopy did not improve Grade‑1 glottic view or first‑attempt success over direct laryngoscopy and modestly prolonged intubation time; complication rates were low and similar.
Impact: Challenges assumptions of routine videolaryngoscopy superiority in elective RSI and directly informs device‑selection policies and training priorities.
Clinical Implications: Supports direct laryngoscopy as appropriate first‑line for routine elective RSI in low‑risk patients, reserving videolaryngoscopy for anticipated or encountered difficult airways.
Key Findings
- No significant difference in Grade‑1 modified Cormack‑Lehane view (46.6% VL vs 42.3% DL; P=0.26).
- First‑attempt success similar (86.5% VL vs 87.6% DL; P=0.76).
- Intubation time modestly longer with McGrath (median 35 s vs 30 s; P=0.016).
5. Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study.
A bicentric ICU cohort of C. auris–colonized patients yielded the four‑variable AURIS score (TPN, prior antifungal therapy, multifocal colonization, urinary isolation) with AUC 0.81, outperforming the Candida score and enabling de‑escalation of empiric antifungals in low‑risk patients (NPV 0.94 at a 28% threshold).
Impact: Provides a validated, pragmatic risk tool for a high‑consequence, multidrug‑resistant ICU pathogen, directly informing antifungal stewardship and diagnostic prioritization.
Clinical Implications: Use AURIS to stratify risk among C. auris–colonized ICU patients: withhold or de‑escalate empiric antifungals in low‑risk profiles and prioritize diagnostics/treatment for high‑risk patients.
Key Findings
- Four predictors retained: TPN, prior antifungal therapy, multifocal colonization, urinary isolation.
- AURIS achieved AUC 0.81 and outperformed the Candida score (AUC 0.75).
- At a 28% threshold: sensitivity 0.72, specificity 0.84, NPV 0.94.